Esperion Therapeutics (ESPR) 10-Q2022 Q1 Quarterly report

Filed: 3 May 22, 8:57am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: accessible, assumed, bank, Bartram, bearing, biotech, cardiometabolic, created, decision, differentiated, director, Dr, fill, fourth, fulfilling, gain, identification, individual, Koenig, lease, line, notified, Omicron, pipeline, recent, resign, resignation, Richard, Rocamboli, role, serve, serving, Sheldon, stand, Stephen, stepping, vacancy, variant, Wainwright, warrant

Removed: affirming, affordable, alter, answer, answering, Antonio, appeal, application, argued, averse, banc, beneficial, blood, Braunstein, breached, broken, calculating, Chancery, Circuit, complaint, Daniel, decline, defendant, denied, derivative, developed, dismissal, Dov, drop, eliminating, embedded, en, Enright, enzyme, EU, failed, FASB, fiduciary, Gilbert, Goldstein, Gotto, hearing, improper, increasing, instrument, Janney, Jr, July, mandate, Mary, McGowan, molecule, motion, Newton, Nicole, nominal, noted, obligated, Omenn, opening, opposition, order, partial, patented, path, Patrick, petition, prejudice, present, regulating, rehearing, reliable, remanded, remove, removing, reply, respond, reversed, Roger, Scott, separation, Serometrix, small, stop, Subtopic, summary, Supreme, Vitullo

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ESPR transcripts

ESPR similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q of Esperion Therapeutics, Inc. (the “Company”) for the period ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of Esperion Therapeutics, Inc., hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that, to my knowledge as of the date hereof:

1)the Report which this statement accompanies fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:	May 3, 2022	/s/ Sheldon L. Koenig
		Sheldon L. Koenig
		President and Chief Executive Officer
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)